chartexchange

Orthofix Reports Third Quarter 2026 Results and Revises Full-Year 2026 Guidance

Business Wire | Nov 9, 2026 7:00 AM EST

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance. Unless otherwise noted, pro forma results exclude the impact of the discontinued M6™ product lines. Third Quarter 2026 Highlights Total reported net sales of $207.9 million, representing an increase of 1% on a reported b

Read original article